Request PDF on ResearchGate | On Feb 1, , Hugo Donato and others published Tratamiento con eritropoyetina humana recombinante. Se demostró que el tratamiento con eritropoyetina humana recombinante (EPO rHu) en pacientes en diálisis es altamente efectivo en cuanto a la corrección de. Eritropoyetina humana recombinante para la anemia de la insuficiencia renal crónica en pacientes en prediálisis. This is not the most recent version of this.
|Published (Last):||23 March 2016|
|PDF File Size:||4.64 Mb|
|ePub File Size:||3.62 Mb|
|Price:||Free* [*Free Regsitration Required]|
Djukanovic Lj, Radovanovic Z. Our patients had iron reserves above the upper limit of normal and a similar proportion of subjects from each group used iron supplements.
After beta-Epo administration plasma Epo slowly increased and C max was achieved after J Am Soc Nephrol ;5: The originating document has been archived.
NDT Plus ;2 Suppl 1: We comply with the HONcode standard for trustworthy health information – verify here.
Eritropoyetina Humana Recombinante –
We recently showed that BEN hemodialysis patients required a higher dose of recombinant human erythropoietin for maintaining the target hemoglobin level than patients with other kidney diseases. By clicking Subscribe, I agree to the Drugs. Endemic nephropathy in Yugoslavia. Anaemia in Balkan endemic nephropathy.
Eritropoyetina Humana Recombinante Delta
Therefore, not only the distribution by itself, eritropooyetina also the process of elimination and interaction directly with the Epo receptor on the red blood cell surface play an important role in increasing the values of Vd for Epo in comparison to its physiological distribution limited to extravascular space in the body.
A number of pharmacokinetic studies of ESA have been published, but hkmana between them is difficult due to numerous methodological differences. N Recmbinante J Med ; These differences remained significant after adjustment for patient characteristics age, sex, hemodialysis duration, ferritin, PTH and ACEI use.
The results were expressed as mean values with standard deviations. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. When adjusted these differences remained statistically significant 0.
Blood samples were centrifuged for 10 min and plasma stored frozen until analysis. Pharmacokinetic analysis of beta-erythropoietin detected a significantly longer elimination half-life in BEN than in non BEN patients. Endemic Balkan Nephropathy, Proc.
J Clin Pharmacol The relevant pharmacokinetic parameters were calculated after noncompartmental pharmacokinetic analysis using Kinetica software Thermo Scientific, ver. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites.
Introduction Anemia was described as a characteristic of Balkan endemic nephropathy BEN in early reports on the disease, 1,2 so Danilovic 3 included it among the criteria for diagnosis. C reactive protein; Epo: All analyses were performed using the SPSS ver.
Analysis of covariance Eritropoyetins was used to adjust these differences for patient characteristics that differed between groups: Similar inter-individual differences were found in time needed to reach Epo C max.
It seems most likely that both native Epo and recombinant drugs are degraded following receptor-mediated uptake, mainly in the bone marrow. Statistical analysis The results were expressed as mean values with standard deviations. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients.
The pharmacokinetic parameters of Epo are presented in Table 3. Endemic nephropathy in Bosnia. Balkan endemic nephropathy BEN hemodialysis patients require a higher dose of recombinant human erythropoietin for maintaining target hemoglobin level than patients with other kidney diseases.
Although basal plasma Epo concentration was similar in BEN Results of laboratory analyses in examined patients CRP: Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
Nephrol Dial Transplant ;19 Suppl 2: Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. Eur J Clin Pharmacol ; In addition, none of gecombinante mentioned factors for Epo hyporesponsiveness were significantly more pronounced in BEN than in non-BEN patients, except for older age.
Consult with your healthcare professional before taking any medication. Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist ERA in healthy volunteers. Serum levels of iron, ferritin, transferrin saturation, C-reactive protein CRPalbumin, urea, creatinine, calcium, phosphorus and parathyroid hormone PTH were determined in each patient at the time of study.
This work was conducted as a part of egitropoyetina No and funded by the Ministry of Science, Education and Technological Development, Belgrade, Republic of Serbia.
Der Mechanismus der Anaemie bie der endemische Nephropathie.